You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華東醫藥(000963.SZ):將積極推動更多國外高端創新醫美產品引入海南博鰲樂城國際醫療旅遊先行區
格隆匯 03-03 21:23

格隆匯3月3日丨華東醫藥(000963.SZ)近日接受機構調研,就“消費者去香港打少女針的話,這塊收入如何計算?”時表示,公司Ellansé®產品在香港的銷售推廣是由第三方經銷商代理,因此,正規Ellansé®產品在香港地區的收入歸屬於公司英國全資子公司Sinclair。

另外,就“公司醫美未來2-3年內會在國內上市的產品有哪些?”時表示,今年,公司引進愛爾蘭EMA公司的面部皮膚管理設備Préime DermaFacial有望在中國上市,醫美全資子公司Viora公司的Reaction™也將重新登陸中國市場,公司已組建專職銷售推廣團隊,並制定了各個產品的整體市場定位及市場推廣計劃。

另外,公司正在積極推進Cooltech Define、V系列產品(V20、V30)、Primelase等身體塑形以及脱毛類的醫美能量源器械產品的國內註冊,將在2024年底陸續上市,MaiLi®、伊妍仕®M型以及Lanluma®等注射類產品正在進行國內臨牀試驗,預計將在2025年上市,其中Lanluma®已經先行獲批落地海南博鰲樂城,公司也將積極推動更多國外高端創新醫美產品引入海南博鰲樂城國際醫療旅遊先行區,讓中國消費者不出國門就能同步體驗全球最新產品。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account